Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice- prone region of the dystrophin COOH terminus by unknown
Mammalian etl- and/ l-Syntrophin  Bind to the Alternative Splice-prone 
Region of the Dystrophin COOH Terminus 
Atsushi Suzuki, Mikiharu Yoshida, and Eijiro Ozawa 
Department of Cell Biology, National Institute of Neuroscience, NCNP, 4-1-10gawa-Higashi, Kodaira, Tokyo,  Japan 
Abstract.  The carboxy-terminal region of dystrophin 
has been suggested to be crucially important for its 
function to prevent muscle degeneration.  We have pre- 
viously shown that this region is the locus that inter- 
acts with the sarcolemmal glycoprotein complex, 
which mediates membrane anchoring of dystrophin,  as 
well as with the cytoplasmic peripheral  membrane 
protein,  A0 and/31-syntrophin  (Suzuki, A.,  M. 
Yoshida, K.  Hayashi, Y.  Mizuno,  Y.  Hagiwara,  and E. 
Ozawa.  1994.  Eur.  J.  Biochem. 220:283-292).  In this 
work, by using the overlay assay technique developed 
previously, we further analyzed the dystrophin- 
syntrophin/A0 interaction.  Two forms of mammalian 
syntrophin,  al- and Bl-syntrophin,  were found to bind 
to very close but discrete regions on the dystrophin 
molecule.  Their binding  sites are located at the vicin- 
ity of the glycoprotein-binding site, and correspond to 
the amino acid residues encoded by exons 73-74 
which are alternatively spliced out in some isoforms. 
This suggests that the function of syntrophin is tightly 
linked to the functional diversity among dystrophin 
isoforms. Pathologically, it is important that the bind- 
ing site for od-syntrophin,  which is predominantly ex- 
pressed in skeletal muscle, coincides with the region 
whose deletion was suggested to result in a  severe 
phenotype. In addition,  A0, a minor component of 
dystrophin-associated proteins with a molecular mass 
of 94 kD which is immunochemically related to syn- 
trophin,  binds to the same site as ~-syntrophin. 
Finally, based on our accumulated evidence, we pro- 
pose a revised model of the domain organization of 
dystrophin from the view point of protein-protein in- 
teractions. 
VSTROPHIN, the  protein  product  of the  Duchenne 
muscular  dystrophy  (DMD) ~ gene,  is  a  spectrin- 
like, long slender protein with a molecular mass of 
427 kD CKoenig et al.,  1987, 1988; Hoffman and Kunkel, 
1989). Immunohistochemicai  and biochemical studies have 
revealed that it is located on the cytoplasmic surface of the 
sarcolemma and  works as a  major component of subsar- 
colemmal cytoskeleton (Watkins et al., 1988; Arahata et al., 
1988; Ohlendieck et al.,  1991). Although  the defect of this 
protein has been shown to cause DMD, the molecular mech- 
anism underlying  this  muscle degeneration  process is not 
well understood yet. 
We have focused our attention  to the COOH-terminal re- 
gion of dystrophin,  because this region has been suggested 
to be pathologically  important  (Beggs et al.,  1991). Our 
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previous work has proven that this region is involved in inter- 
actions  with  a  number  of dystrophin-associated  proteins 
(DAPs),  including the components of the sarcolemmal  gly- 
coprotein complex (GPC)  which mediates  membrane  an- 
choring  of dystrophin  (Yoshida and Ozawa,  1990;  Suzuki 
et  al.,  1992,  1994).  GPC  is  composed of at  least  four 
membrane-spanning  glycoproteins (adhalin [50DAG], 13-dys- 
troglycan [43DAG], A3b and 35DAG) and one extracellular 
proteoglycan  (c~-dystroglycan [156DAG]) (Ervasti  et  al., 
1990;  Yoshida and  Ozawa,  1990;  Ervasti  and  Campbell, 
1991; Ibraghimov-Beskrovnaya  et al.,  1992,  1993; Roberds 
et al., 1993). The GPC-binding  site on dystrophin is located 
in a widely extended region encompassing  the cysteine-rich 
domain  and the first  half of the  COOH-terminal  domain 
(Suzuki et al., 1992,  1994), the deletion of which had been 
shown to obligatorily lead to severe phenotypes (Beggs et 
al.,  1991). Therefore,  the lack of interaction  between this 
COOH-terminal region and GPC was suggested to be one of 
the essential causes of the disease. On the other hand, among 
the components of GPC, the protein which directly interacts 
with this GPC-binding  site is B-dystroglycan (Suzuki et al., 
1994). From our recent studies which showed that/~-dystro- 
glycan extracellularly  binds to the laminin-binding  ct-dystro- 
glycan and forms a distinctive  subcomplex in GPC named 
©  The Rockefeller  University  Press, 0021-9525/95/02/373/9  $2.00 
The Journal of Cell Biology, Volume 128, Number 3, February  1995 373-381  373 dystroglycan complex, we suggest that the interaction be- 
tween dystrophin and the dystroglycan  complex may serve an 
essential link between dystrophin and the extracellular ma- 
trix  (Ibraghimov-Beskrovnaya et  al.,  1992;  Ervasti  and 
Campbell, 1993; Suzuki et al., 1994; Yoshida et al., 1994). 
The NH2-terminal  domain of dystrophin has been shown 
to bind actin filaments in vitro (Way et al., 1992; Ervasti and 
Campbell, 1993). Therefore, it has been postulated that dys- 
trophin mediates the linkage between the extracellular ma- 
trix and the actin-based subsarcolemmal cytoskeleton, and 
the disruption of  this linkage results in the damage of  the sar- 
colemma, which, in turn, leads to muscular degeneration 
(Ervasti  and Campbell,  1993;  Ohlendieck et  al.,  1993). 
However, recent results indicated that, even in the presence 
of this linkage, muscles may degenerate (Matsumura et al., 
1992; Yamanouchi et al., 1994; Mizuno et al., 1994): in the 
skeletal muscle of the other type of muscular dystrophy (se- 
vere  childhood  autosomal  recessive  muscular  dystrophy 
[SCARMD]) and its animal model, dystrophin and the dys- 
troglycan complex are expressed almost normally and show 
normal membrane localization, whereas other components 
of GPC, namely adhalin, 35DAG and A3b, which form the 
other  subcomplex  in  GPC  named  sarcoglycan  complex 
(Yoshida et al., 1994), are selectively reduced. Therefore, it 
is beginning to appear that, as a complicated protein com- 
plex constituted by the dystroglycan and sarcoglycan sub- 
complexes, GPC not only serves a membrane-anchoring site 
for dystrophin, but also exerts a more sophisticated function 
which is crucial for muscle fiber maintenance. In this sense, 
the COOH-terminal region of dystrophin becomes more im- 
portant as a locus where complicated protein-protein inter- 
actions may occur (Bowe et al.,  1994). 
In addition to the sarcolemmal glycoproteins in GPC, the 
cytosolic peripheral  membrane proteins,  A0 and ot-/fl-A1 
(59DAP),  have been reported to be copurified with rabbit 
skeletal muscle dystrophin (Ervasti et al., 1990; Yoshida and 
Ozawa, 1990;  Ervasti and Campbell, 1991). Among them, 
or-  and fl-A1 were  recently shown to be  the mammalian 
homologues of a Torpedo 58-kD postsynaptic protein, syn- 
trophin, which has been suggested to be involved in cluster- 
ing acetylcholine receptors (Froehner 1984,  1987; Adams et 
al., 1993; Alan et al., 1994; Yang et al., 1994). In agreement 
with other laboratories, we renamed a- and fl-A1 as t~l- and 
fll-syntrophin,  respectively  (Peters  et  al.,  1994).  In  the 
previous paper,  we have shown that A0 and fll-syntrophin 
also bind to the dystrophin COOH-terminal region directly, 
and their binding sites are located within the distal half of 
the COOH-terminal domain (Suzuki et al.,  1994).  In the 
present paper, we advanced the analysis on the binding site 
for fll-syntrophin and A0 by using the overlay assay method 
we developed previously (Suzuki et al., 1994). In the course 
of this study, we found that not only fll-syntrophin but also 
od-syntrophin  (syntrophin-1,  59DAP-I),  binds  directly  to 
dystrophin. The defined binding sites for the two syntrophin 
isoforms are located very close to each other on the dystro- 
plain molecule but are made up of  completely different  amino 
acid sequences. Interestingly, both binding sites are confined 
within the region which is alternatively spliced out depend- 
ing on tissue types (Feener et al., 1989; Bies et al., 1992). 
The results we obtained here may provide important clues 
for the biological function of syntrophins. 
Materials and Methods 
Expression and Purification of 
Dystrophin Deletion Mutants as Fusion Proteins 
with Glutathione-S-Transferase 
All  deletion mutant constructs shown  in  Fig.  1  were  generated  from 
pGEX/DCT685 described previously (Suzuki et al., 1994) using restriction 
enzymes.  This construct contained the 3.7-kb HindIII fragment of dystro- 
phin encoding the COOH-terminal residues  3026-3685,  which we ligeted 
into the EcoRI site of pGEX-3X (Pharmacia LKB Biotechnology,  Piscata- 
way, NJ) using HindIII-EcoRI adapters made by mixing EcoRI-SmaI and 
HindIII-EcoRI adapters  (Takara Shuzo Co., Ltd., Kyoto, Japan).  During 
the construction of deletion mutants, the correct colonies were verified by 
restriction mapping of the recombinant plasmids or immunoscreening with 
region-specific  anti-dystrophin antibodies (see Fig.  1). 
A COOH-terminal deletion mutant, pGEX/DCT535,  was constructed by 
a cut of the pGEX/DCT685 at a convenient XbaI site within the 3' untrans- 
lated region (UTR) and at a StuI site, followed by end blunting and religa- 
tion. For construction of pGEX/DCT263-685 and pGEX/DCT536-685,  a 
3.2-kb BamHI-EcoRI fragment of pGEX/DCT685 was at first subcloned 
into pGEX-2T to adjust the reading  frame: pGEX/DCT685 was digested 
with BamHI and EcoRI and the 3.2-kb restriction fragment derived from 
the insert was purified from an agaroso gel and religated into complemen- 
tary sites in pGEX-2T. The resultant  plasmid was digested by BamI-II/AccIlI 
for pGEX/DCT264-685  or by BamHI-StuI for pGEX/DCT536-685  and 
religated  after end blunting, pGEX/DCT444-685 was constructed by the 
use of a NheI site within the COOH-terminal coding sequence. To achieve 
this, the NheI site in the 3' untranslated region was first deleted as follows. 
pGEX/DCT685 was digested with BamHl and religated to remove nucleo- 
tides containing the EcoRI site in the 5' polylinker site (PLS).  The cloned 
plasmid, which was named pGEX/DCT194-685,  was then cut at an XbaI 
site in the 3' untranslated region, and at an EcoRI site in the 3' polylinker 
site to remove nucleotides containing the second NheI site. After the resul- 
tant plasmid was blunt ended, religeted,  and cloned, the construct pOEX/ 
DCT444-685 was generated by a cut of the plasmid with Baml~-NheI and 
religeted after end blunting. To generate pGEX/DCT444-535 and pGEX/ 
DCT444-494,  pGEX/DCTI94-685  was  digested  with  StuI-SmaI  and 
Bglll-SmaI, respectively,  blunt ended and religated.  This procedure re- 
moved the second NheI site in the 3' untranslated region. Each cloned plas- 
mid  was  then processed  by BamI-II-NheI  digestion,  blunt ended,  and 
religated. 
Expression and Purification of the Fusion Proteins 
Recombinant proteins were expressed in E. coli and purified from the solu- 
ble fraction of cell lysates with the glutathione-Sepharose  column essen- 
tially as  described previously  (Suzuki  et al.,  1994).  The  Ion- mutant 
(ME8426)  of E.  coil  was also used as a host strain for the expression of 
DCT685, DCT535, DCT442, DCT264, and DCT264-685, since these were 
very susceptible to bacterially endogeneous proteases.  To remove degrada- 
tion products with low molecular masses,  gel filtration was performed for 
these constructs on Superose  12 (Pharmacia LKB Biotechnology).  For the 
other fusion proteins which were stably expressed,  the strain HB101 was 
used and the gel-filtration procedure was omitted. As we described previ- 
ously (Suzuki et al., 1994), the original method (Smith and Johnson, 1988) 
of purifying the GST-fusion proteins was modified by the addition of a wash- 
ing procedure of the glutathione-Sepharose resin-adsorbed fusion proteins 
with PBS (150 mM NaC1, 10 mM NaH2PO4/NaOH,  pH 7.5) containing 3 
mM Mg-ATP, 1 mM DTT and proteinase inhibitors (2 #g/ml leupeptin, 0.5 
#g/nil aprotinin, 1 mM benzamidine and 0.1 mM PMSF). This procedure 
eliminates contaminating E.  coil DnaK (the analog of the vertebrate heat- 
shock protein 70). In the case of DCT264-685  purification,  this washing 
buffer was changed to a caseirdMg-ATP buffer (30 mM Tris/HCI,  50 mM 
KCI, 5 mg/ml casein, 10 mM MgCI2, 10 mM ATE 2 mM DTT and inhibi- 
tors, pH 7.5), and the washing period was prolonged to more than 20 rain 
at room temperature,  because the sample contained E. coil GroEL (the ana- 
log of the vertebrate heat-shock protein 60) in addition to DnaK. 
Overlay-binding Assay 
The overlay-binding  assay  was  also performed as  previously  described 
(Suzuki et al., 1994). Briefly, dystrophin-DAP complex (l #g) purified from 
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electrophoretically separated on a 10% gel by SDS-PAGE  and transferred 
onto a polyvinylidene difluoride membrane. After being blocked with the 
PBS containing 0.1% casein and 0.1% gelatin overnight at 4"C, the mem- 
brane was incubated with purified fusion proteins for 2 h at room tempera- 
ture in the presence of 1 mM DTT. Bound fusion proteins were detected 
with anti-dystrophin antibodies. 
• Electrophoresis  and Immunostaining Analysis 
For overlay assay, SDS-PAGE and protein  transfer to a  polyvinylidene 
difluoride membrane were performed as described (Laemmli, 1970; Kyhse- 
Anderson, 1984). For characterization of the expressed fusion proteins, we 
used an automated electrophoresis system, Phast System (Pharmacia LKB 
Biotechnology), using the 12.5  % precast mini-gel PhastGel for convenience 
and saving samples. Two-dimensional PAGE  was performed essentially ac- 
cording to the method of  O'Farrell as described previously (O'Farrell, 1975; 
Yamamoto et al., 1993). Briefly, 1 /~g of dystrophin-DAP complex dena- 
tured with 8 M urea and 2% ~-mercaptcethanol was isoelectrophoretically 
separated on 1% polyacrylamide capillary gel (4 cm ×  1 mm i.d.) contain- 
ing 8 M urea, 0.5%  NP-40 and 2%  Ampholine pH  3.5-10. After being 
equilibrated with a solution containing 0.15 M Tris/HCl (pH 6.8), 2% SDS, 
5 % B-mercaptoethanol  and 10 % glycerol, the capillary gel was placed later- 
ally on top of a 10% slab gel and subjected to SDS-PAGE.  Immunostaining 
was carried out by the use of the Vectastain ABC kit (Vector Labs., Inc., 
Burlingame, CA) for fusion protein characterization or the Elite ABC kit 
for overlay assay. 
Antibodies 
The region-specific  anti-dystrophin antibodies used in this study were as fol- 
lows. The polyclonal antibodies P31b, P33c, and P34a, which were previ- 
ously reported  (Tanaka et al.,  1989; Suzuki et al.,  1992), were raised 
against the  synthetic polypeptides corresponding to the  amino acid  se- 
quences  of human  dystrophin 3186-3200,  3373-3391, and  3495-3544, 
respectively. A new polyclonal antibody, PEX73, was generated in Japanese 
white rabbits with GST-free DCT444-494 as an antigen. The antigen was 
prepared by digestion of DCT444-494 with thrombin and purified by SDS- 
PAGE on a 20% gel followed by a cut of the corresponding band. A mono- 
clonal antibody, Dy8/6C5, which was raised against the synthetic polypep- 
tide corresponding to the last 17 amino acids at the COOH terminus of the 
human  dystrophin  was  purchased  from  Novocastra Laboratories,  Ltd. 
(NE2, 4AA, UK) 
Peptides 
P34 peptide, which corresponds to the amino acid residues 3495-3544 of 
the human dystrophin sequence, was the same as the one used for prepara- 
tion of the region-specific anti-dystrophin antibody P34a (Tanaka et al., 
1989). 
Results 
Expression  and Purification  of  Dystrophin Mutants 
In our previous work,  we constructed a  dystrophin fusion 
protein,  DCT685  (Fig.  1),  which expresses  the dystrophin 
COOH-terminal amino acid residues corresponding to the 
cysteine-rich  domain  and  the  entire  COOH-terminal  do- 
main,  and  found that  it  specifically binds to  three  DAPs, 
~dystroglycan (43DAG),  A0,  and fll-syntrophin (Suzuki et 
al.,  1994; see Fig. 3 lane 3). In that work, by using the two 
COOH-terminal deletion mutants of DCT685, DCT442, and 
DCT264,  we  mainly  studied  the  interaction between  the 
GPC-binding site and/3-dystroglycan. In the present work, 
to focus on the interactions of dystrophin COOH terminus 
with A0 and/31-syntrophin and confine their binding site(s), 
we newly constructed three kinds of NH2-terminal deletion 
mutants of DCT685,  namely, DCT264-685,  DCT444-685, 
and DCT536-685, as well as one additional COOH-terminal 
deletion mutant, DCT535  (Fig.  1).  In Fig.  2  a  the typical 
SDS-PAGE pattern of each fusion protein sample used for 
the following assays is shown. All of them were confirmed 
to  be  reasonably  recognized  by  the  predictable  region- 
specific anti-dystrophin antibodies shown in Fig.  1 (data not 
shown). 
Binding Site(s) for AO and [31-Syntrophin Reside 
within Residues 3444-3535 
Dystrophin  fusion  proteins  were  examined  for  the  DAP- 
binding activity by the blot overlay assay  (Fig.  3).  As  we 
Figure 1.  A Schematic diagram of dys- 
trophin  deletion  mutants  fused  to 
glutathione-S-transferase  (GST).  The 
largest bar is a schematic representation 
oftbe dystrophin COOH terminus show- 
ing the domain organization predicted 
by Kunkel and  co-workers  (Koenig et 
al., 1988; Hoffman and Kunkel, 1989). 
The restriction endonuclease sites used 
to  construct  truncated  dystrophin  ex- 
pression vector and the amino acid scale 
are illustrated above the dystrophin dia- 
gram. Vertical lines below the diagram 
show the position of the cysteine resi- 
dues.  Some of the reported alternative 
splicing patterns of exons 71-74 are also 
indicated (Feener et al.,  1989; Bies et 
al., 1992). Shaded bars indicate the lo- 
cations of GPC- and syntrophin-binding 
sites defined in the previous (Suzuki et 
al., 1992, 1994) and the present studies, 
respectively. A set of smaller bars below 
shows the locations of the constructed 
fusion proteins and a synthetic peptide, 
P34 peptide. The locations of the epitopes for the region-specific anti-dystrophin antibodies used in this study are shown by black bars. 
The results of the overlay assay method presented here are summarized on the right of each fusion protein. 
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structed dystrophin-deletion mutants. Dystrophin-DAP  complex (1 
/xg) was separated on a 10% gel by SDS-PAGE  and transferred onto 
a polyvinylidene difluoride membrane. Blot overlay  was carried out 
as described previously (Suzuki et al., 1994). The fusion proteins 
used are indicated at the top of the lanes, except for CBB, which 
means a Coomasie blue-stained  blot which is not processed by 
overlay (lane 1 ). Some of the lanes are from separate experiments. 
The protein concentration of each fusion protein sample overlaid 
(10-20 #g/nil) was adjusted so as to give clear results. The positions 
of DAPs and the anti-dystrophin antibodies used are indicated on 
the left and at the bottom,  respectively. 
Figure 2.  Purification and characterization of the constructed fu- 
sion proteins. (a) The typical SDS-PAGE patterns of the purified 
fusion proteins stained by Coomasie brilliant blue are shown. (b) 
(Lane 1 ) The specificity of  the newly prepared anti-dystrophin anti- 
body, PEX73. PEX73 reacts with dystrophin in the purified dystro- 
phin-DAP complex. (lanes 2-7) Characterization of DCT444-535 
(lanes 2, 4, and 6) and DCT444-494 (lanes 3, 5, and 7) with the 
three  region-specific anti-dystrophin antibodies indicated at the 
bottom. 
showed previously (Suzuki et al., 1994), the binding of dys- 
trophin  COOH  terminus  to  A0  and  /31-syntrophin  is  dis- 
rupted if the residues downstream from 3443  are deleted 
(lanes 5  and  6).  On the other hand,  a  newly constructed 
COOH-terminal deletion mutant, DCT535 retains the bind- 
ing ability to both At) and/31-syntrophin, suggesting that the 
amino acid residues 3443-3535 are essential for this binding 
(lane 4). Next, a series of fusion proteins with progressive 
NH2-terminal deletions of DCT685 (lanes 8-11 ) was exam- 
ined.  NH2-terminal deletions up to residue  3443  did not 
significantly affect the binding (lanes 9 and 10), while fur- 
ther  NH~-terminal  deletion  (DCT536-685)  resulted  in  a 
dramatic reduction in the binding (lane 11 ). A low affinity- 
binding site may exist within the residues 3536-3685,  be- 
cause very weak staining of A0 and/31-syntrophin was ob- 
served in  lane  11.  However, these  deletional  analyses  of 
DCT685 from both directions collectively indicated that the 
essential binding  site(s)  for A0  and  /31-syntrophin  resides 
within the residues between 3444-3535. 
~l-Syntrophin Binds to the Dystrophin COOH 
Terminus as Well as [31-Syntrophin 
In non-skeletal muscle tissues such as heart and brain, four 
tandem exons, 71-74, of the DMD gene are differentially 
spliced in at least l0 separate patterns to generate the distinct 
dystrophin isoforms (Feener et al., 1989; Bies et al., 1992). 
Interestingly, the essential binding region for A0 and/31- 
syntrophin defined above  closely corresponds to  the  se- 
quence  encoded  by  exon  73-74  (Fig.  1).  Therefore,  to 
confirm the above results and confine the binding  site(s) 
more precisely in  relation to  the  exon structure of dys- 
trophin,  we  constructed  two  additional  fusion  proteins, 
DCT444-535 and DCT444-494 (Figs.  1 and 6). As shown 
in Fig. 2, a and b, both fusion proteins were purified without 
any degradation fragments and were reasonably recognized 
with the region-specific anti-dystrophin antibodies including 
PEX73 which was newly generated using DCT444-494 as 
an antigen. 
Fig. 4 a  shows the results of the overlay assay with these 
fusion proteins. As expected, DCT444-535 strongly reacted 
with A0  and/31-syntrophin,  which is compatible with the 
above results that the residues between 3444-3535 contain 
the essential binding site for A0 and ~l-syntrophin. Further- 
more, DCT444-535 also reacted weakly but distinctly with 
an additional band below the broad staining on ~31-syntrophin 
(lane 3 in Fig. 4 a). This band corresponds to od-syntrophin 
(c~-A1, syntrophin-1 or 59DAP-1),  which exhibits 50%  ho- 
mology with/31-syntrophin but is the product of a different 
gene (Yamamoto et al., 1993; Ahn et al., 1994; Yang et al., 
1994). On the other hand, when the shorter fusion protein 
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syntrophin bind to dystrophin 
COOH-terminal  region.  (a) 
The  results of  overlay as- 
says using DCT444-535 and 
DCT444-494.  The  protein 
concentrations of the overlaid 
samples are 5 and 25 #g/ml 
for DCT444-535 (lanes 2 and 
3, respectively), and 20 #g/ml 
for  DCT444-494  (lane  4). 
The  antibody  PEX73  was 
used  for detection.  (b)  The 
overlay assay onto two dimen- 
sionally separated DAPs. The 
fusion proteins used are indi- 
cated at the top of each panel, 
except for CBB, which  rep- 
resents  the  Coomasie  blue- 
stained  blot  membrane.  On 
the left side of each panel is 
the result of the overlay assays 
performed  on  dystrophin- 
DAP  complex  separated  by 
one-dimensional SDS-PAGE. 
An arrow and an arrowhead in 
each panel indicates the posi- 
tions of  ill- and cd-syntrophin, 
respectively. The  used  anti- 
body is PEX73. 
DCT444-494, which lacks the COOH-terminal half of the 
sequence contained in DCT444-535, was overlaid, A0 and 
~l-syntrophin were not stained, whereas od-syntrophin was 
well stained. 
Previously, we reported that DCT685 binds to A0 and/$1- 
syntrophin (t-A1), but not to od-syntrophin (oL-A1) (Suzuki 
et al., 1994). This conclusion was based on the result of the 
overlay assay onto two dimensionally separated DAPs. In the 
case of DCT685, the staining on syntrophins was too strong 
and broad to analyze one dimensionally. We again failed to 
detect the staining on od-syntrophin using the fusion proteins 
DCT444-535 and DCT444-494 under the same conditions 
as the previous experiment (data not shown). This suggests 
that the experimental conditions using an automated elec- 
trophoresis system with a precast minigel were not suitable 
to detect the weak binding of dystrophin onto od-syntrophin. 
Therefore, in the present study, we improved the experiments 
by using manually cast gels (see Materials and Methods) and 
obtained  results  consistent  with  those  obtained  by  one- 
dimensional SDS-PAGE analysis (Fig.  4  b):  DCT444-535 
bound to not only A0 and fll-syntrophin (arrow) but also 
od-syntrophin (arrowhead), whereas  DCT444-494  bound 
only  to  od-syntrophin.  We  also  confirmed that  DCT685 
bound to od-syntrophin as well as A0,  fll-syntrophin, and 
fl-dystroglycan under these conditions. 
Binding Sites  for ~1- and fl  l-Syntrophin 
Are Separated and Located Tandemly Around 
Alternative Splice-prone Exons 
As shown in Fig.  5  a,  P34 peptide (Tanaka et al.,  1989), 
which covers the non-overlap region between DCT444-535 
and DCT444-494 (Figs.  1 and 6), bound to A0 and/~l-syn- 
trophin  but  not  to  od-syntrophin.  In  addition,  an  excess 
amount of the peptide inhibited the binding of DCT444-535 
to A0 and fll-syntrophin significantly, but not the binding to 
od-syntrophin  (Fig.  5  b).  Hence,  we  concluded  that  (a) 
otl-  and  fll-syntrophin  separately  bind  to  the  dystrophin 
COOH terminus, and (b) the binding site for od-syntrophin 
resides within the amino acid residues  3444-3494,  while 
that  for  A0/fll-syntrophin  resides  within  the  amino  acid 
residues 3495-3535 (Fig. 6). 
Secondary structure analysis (Chou and Fasman,  1978) 
predicted that the binding site for A0/~l-syntrophin forms a 
long a-helix flanked by the proline-rich turn structures (Fig. 
6).  Interestingly, this c~-helix takes a  leucine-zipper motif 
and is rich in acidic residues. Because/~l-syntrophin is a ba- 
sic protein (Yamamoto et al.,  1993), the latter feature of the 
binding site suggested that the electrostatic interaction is im- 
portant for the binding of dystrophin to Bl-syntrophin. How- 
ever,  the  increase of the  ionic  strength  up  to  1  M  NaCI 
scarcely affected the interactions of DCT444-535 to A0//~I- 
syntrophin as well as to od-syntrophin (Fig. 5 c). This may 
indicate that syntrophin binding of dystrophin COOH termi- 
nus involves a predominantly hydrophobic interaction. 
Other Regions May Contribute to the 
Dystrophin-Syntrophin  Interaction 
By performing competition assays between the constructed 
fusion proteins, we examined the syntrophin-binding affinity 
of each dystrophin COOH-terminal sequence. As shown in 
lanes I and 4 of  Fig. 7, DCT444-535, which showed substan- 
tial binding activity to syntrophin (Fig. 4 a), could not inhibit 
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the  binding  between  dystro- 
phin and two forms of syntro- 
phin. (a) An overlay assay was 
performed using P34 peptide 
corresponding  to  the  amino 
acid  residues  3495-3544  of 
human dystrophin as a probe 
(lanes 2 and 3).  Detection of 
bound peptide  was performed 
with the antibody,  P34a. The 
concentrations of the overlaid 
peptide are 170/zg/ml (lane 2) 
and  500  /~g/ml (lane  3).  In 
lanes 4 and 5, the results using 
DCT444-494  and  DCT444- 
535 were shown, respectively, 
for comparison (the used  an- 
tibody  for  detection  was 
PEX73).  (b)  A  competition 
assay  between  DCT444-535 
and P34 peptide.  20/~g/ml of 
DCT444-535  was  overlaid 
with  (lanes  2-4)  or without 
(lane 1 ) an excess amount of P34 peptide.  The concentrations of p34 peptide  are 57 ~g/ml (lane 2), 280 ttg/ml (lane 3), and 1,100 #g/ml 
(lane 4). The binding of  DCT444-535 was selectively detected by the antibody, PEX73. (c) The effect of salt concentration on the interaction 
between DCT444-535 and syntrophins.  The concentrations of sodium chloride in the reconstituting  buffer were changed from 0-1 M as 
indicated. 
syntrophin binding of  the entire COOH-terminal sequence of 
dystrophin (DCT685) even at 20-fold molar excess. This in- 
dicated that the flanking region of the essential binding site 
for syntrophin defined above must contribute to the secure 
binding to syntrophin. In fact, in contrast with DCT444-535, 
DCT444-685,  which  contains  the  distal  full  sequence  of 
COOH-terminal region, was found to compete in the syntro- 
phin binding with DCT685 to some extent (lane 3). There- 
fore, the amino acid residues 3536-3685 may be involved in 
syntrophin binding. This idea was also supported by the re- 
sult of another competition assay (lanes 5 and 6): DCT535, 
which  lacks  this  distal  COOH-terminal  sequence  down- 
Figure 6. Secondary structure analysis of the essential syntrophin-binding region. The amino acid sequence (3438-3557) around the essential 
syntrophin-binding  site  is shown at the top with the predicted  secondary structure  (Chou and Fasman,  1978) and the exon boundaries 
(RJaberts et al.,  1993).  In the Chou and Fasman analysis,  the letters  h, s, t, and c represent  ct-helix,/3-sheet,  turn, and coil structures, 
respectively. Upper case of each letter suggests the most favorable structure for the residue. Note that the ~l-syntrophin-binding site (amino 
acid residues  3495-3535)  is rich in acidic residues  (marked with asterisks)  and is predicted  to take a long c~-helix structure (underlined). 
This c~-helix  contains a stretch of  four leucines in the heptad repeat (underlined),  suggesting that it takes leucine-zipper  motif. These leucine 
residues  are well conserved even in utrophin (Tinsley et al.,  1992). This leucine-zipper  motif precedes the other one which has been sug- 
gested to locate within the amino acid residues  3558-3594 (Wagner et al.,  1993). One of the potential  phosphorylation site by p34  ~c2 is 
boxed (Milner et al.,  1993). The bars below indicate the positions  of DCT444-535, DCT444-494 (black bars), and P34 peptide  (lightly 
shaded bars). 
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tants. 20/~g/ml of DCT685 was overlaid with or without an excess 
amount  of the  deletion  mutant indicated.  The antibodies  used, 
which were chosen to selectively detect the binding of DCT685, are 
indicated at the bottom. The protein concentration of  the coexisting 
fusion proteins  (competitors)  was 250 tLg/ml for all cases. 
stream from residue 3536,  inhibited syntrophin binding of 
DCT685  greatly but  incompletely,  although  it completely 
abolished/3-dystroglycan binding of DCT685. These results 
are consistent with the observation in Fig. 3 which suggested 
that this sequence may contain another low affinity-binding 
site for A0//31-syntrophin. 
On the other hand, the GPC-binding region may also affect 
the  syntrophin  binding  of dystrophin,  because the  inhibi- 
tion  of DCT444-685  against  A0//31-syntrophin  binding  of 
DCT685 was rather incomplete (lane 3).  This was the case 
when  DCT264-685  was used as  a  competitor in  place of 
DCT444-685 0ane 2). These results excluded the possibility 
that the  steric hindrance  arising from fused GST was the 
cause of the incompleteness of the inhibition, and suggested 
that the lack or disruption of the GPC-binding region may 
weaken  the  binding  affinity  of dystrophin  to  A0//31-syn- 
trophin. 
Discussion 
In the present work, by using the overlay assay method, we 
showed that two forms of syntrophin, od- and/31-syntrophin 
(Adams et al.,  1993;  Alan et al.,  1994; Yang et al.,  1994), 
which are the membrane extrinsic proteins (Froehner, 1984; 
Ervasti and Campbell, 1991),  directly bind to dystrophin at 
the vicinity of the GPC-binding site (Fig.  1). Their essential 
binding sites are confined to the region between amino acid 
residues 3444-3535.  In addition, a low afffinity-binding site 
is also suggested to exist at the more COOH-terminal region. 
In Fig. 8, we propose a new idea on the domain organiza- 
tion of the dystrophin COOH-terminal region from the view- 
point of protein-protein interactions: the cysteine-rich do- 
main and the first half of the COOH-terminal domain are 
together renamed "the dystroglycan-binding domain" (amino 
acid residues 3080-3408), since this region binds to the dys- 
troglycan complex as a single functional unit (Suzuki et al., 
1994).  It  should  be  noted  that  this  domain  is  a  genuine 
"cysteine-rich region" in which the well-conserved cysteine 
residues are concentrated (see Figs. 1 and 8). As we demon- 
strated previously, these cysteine residues are important for 
the binding to/3-dystroglycan (Suzuki et al.,  1994). 
On  the  other  hand,  since  the  last  half of the  COOH- 
terminal domain,  which  is  not essential  for GPC binding 
(Suzuki et al., 1992,  1994), forms a domain to interact with 
syntrophins, we propose to call this region "the syntrophin- 
binding domain" (amino acid residues 3409-3685).  This do- 
main contains two leucine-zipper motifs possibly important 
Figure 8. A new model of the 
domain  organization  of  the 
dystrophin  COOH  terminus 
from  the  viewpoint  of pro- 
tein-protein  interactions. The 
original model (top) based on 
the amino acid sequence anal- 
ysis  (Koenig  et  al.,  1988; 
Hoffman  and  Kunkel,  1989) 
and  a  new  model  (bottom) 
based on the results of DAP- 
binding  activities  and  the 
limited  digestion  of  dystro- 
phin  (Suzuki  et  al.,  1992; 
Yoshida et al., 1992; Suzuki et 
al.,  1994; and  the  present 
work) are illustrated.  The difference between the two lies at the COOH-terminal  end of dystrophin, where the cysteine-rich domain and 
the first half of the COOH-terminal domain in the original model are combined to form "the dystroglycan-binding domain" (amino acid 
residues 3080-3408) in the new model (Suzuki et al.,  1994). The remaining distal part of the dystrophin COOH terminus (amino acid 
residues 3409-3685), which corresponds to the last half of the COOH-terminal domain in the original model, is suggested to interact with 
syntrophin, thus designated as "syntrophin-binding domain:' A0, a minor dystrophin-associated protein with a molecular mass of 97 kD 
which is immunochemically related to syntrophin,  also binds to this domain.  The vertical lines represent the positions of the cysteine 
residues.  Alternative splicing patterns so far reported are also indicated (Feener et al.,  1989; Bies et al.,  1992). 
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to the amino acid residues 3498-3533  [first suggested in this 
paper ; see Fig. 6] and the other corresponds to the residues 
3558-3594  [Wagner et al.,  1993]).  We identified here that 
the proximal motif coincides with the essential binding site 
for/31-syntrophin.  The syntrophin-binding domain also con- 
tains two predicted phosphorylation sites by p34  cdc~ (Milner 
et al., 1993), one of which is located within the intermediate 
region of the two leucine zipper motifs (Fig. 6).  Together 
with the fact that this domain contains the alternative splice- 
prone region (Fig. 8; Feener et al., 1989; Bies et al., 1992), 
these results imply that this is the locus of various regulatory 
activities for dystrophin function. Because this domain is 
very susceptible to proteinase digestion, it is considered not 
to  have a  tightly packed  structure  (Suzuki  et  al.,  1992; 
Yoshida et al.,  1992). 
It may be of biological importance that the essential syn- 
trophin-binding site defined here (amino acid residues 3444- 
3535)  coincides with the region which is subjected to the 
tissue-type specific alternative splicing (Fenner et al., 1989; 
Bies et al.,  1992).  This is consistent with the results of 
Ahn et al.  (1994) that the sequence encoded by exon 74 
is the site for/31-syntrophin binding (the accompanied pa- 
per).  This means that the function of syntrophin is tightly 
linked to the isoform-specific function of dystrophin, and 
some dystrophin isoforms may function without interacting 
with syntrophins. Most tissues express multiple isoforms of 
dystrophin, suggesting that multiple functions of dystrophin 
are required even in a single cell (Bies et al., 1992).  As for 
the isoforms lacking the region encoded by exon 74, they are 
predominantly detected in brain, heart and smooth muscles, 
but very rarely in skeletal muscles (Bies et al., 1992). These 
results indicate that the interaction with syntrophins is in- 
dispensable for skeletal muscle dystrophin. This represents 
a keen coincidence with the components of the sarcoglycan 
complex (Adhalin, A3b and 35DAG) which are solely ex- 
pressed in the striated muscles (Roberds et al., 1993; Mizuno 
et al.,  1993;  Yamamoto et al.,  1994) and the loss or great 
reduction of which is commonly observed in both SCARMD 
and DMD (Matsumura et al.,  1992;  Mizuno et al.,  1994; 
Yamanouchi et al., 1994). This might also suggest that syn- 
trophins work cooperatively with sarcoglycan complex in the 
modulation of the symptoms. Indeed, the binding site for 
od-syntrophin, which is predominantly expressed in skeletal 
muscle (Adams et al.,  1993;  Yang et al.,  1994),  precisely 
matches  amino acid residues  3444-3485,  the deletion of 
which causes a phenotype showing severe muscle wasting 
(Roberts et al., 1992).  In this sense, it is a challenging sub- 
ject to clarify whether the direct interaction between syntro- 
phin and the components of GPC exists or not. 
Recent works on cDNA cloning established the heteroge- 
neity of the mammalian syntrophin (Adams et al., 1993; Ahn 
et al., 1994; Yang et al., 1994): there are three forms of syn- 
trophin (cd-,/31-, and/~2-syntrophin), which originate from 
different genes (their nomenclature was given in Peters et al. 
[1994]). In the present work, we have shown that or- and/31- 
syntrophin bind to very close but discrete sites on dystro- 
phin. Considering the overall homology (50%) between the 
two forms of syntrophin (Alan et al., 1994),  it is interesting 
that they bind to completely different amino acid sequences 
on the dystrophin molecule (Fig. 6): the binding site for cd- 
syntrophin (amino acid residues 3444-3494)  did not show 
affinity  to/31-syntrophin,  and vice versa (Figs. 4 and 5). This 
finding leads to the suggestion that the amino acid sequence 
of each syntrophin involved in the interaction with dystro- 
phin should be different from the other. It is tempting to con- 
sider that the functional diversity of syntrophins is mostly 
localized in their respective interaction regions with dystro- 
phin. One might consider the possibility that the bindings of 
ed- and/31-syntrophins are mutually exclusive,  because the 
binding loci for both syntrophins are too close (Fig. 6). How- 
ever, this possibility may be excluded by our preliminary ob- 
servation that al-  and  /31-syntrophin  associate  with each 
other (Yoshida and Ozawa, 1990). Therefore, it is likely that 
or- and/31-syntrophin bind to a single dystrophin molecule 
in the fixed arrangement simultaneously. 
Finally, we observed that A0 binds to dystrophin at the 
same region as/31-syntrophin. This protein, with a molecular 
mass of 94 kD, is a minor component of dystrophin-DAP 
complex purified from sarcolemma. Because At) shows simi- 
lar biochemical nature to syntrophin and cross-reacts with 
an anti-syntrophin antibody (Yamamoto et al.,  1993),  A0 
may also be a member of the syntrophin family. 
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